Skip to Content

Milestone Pharmaceuticals Inc.

Securities Class Action

  • Date:
  • 1/18/2024
  • Company Name:
  • Milestone Pharmaceuticals Inc.
  • Stock Symbol:
  • MIST
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) (NASDAQ: MIST) on behalf of Milestone stockholders. Our investigation concerns whether Milestone has violated the federal securities laws and/or engaged in other unlawful business practices.

On December 26, 2023, before the market opened, Milestone Pharmaceuticals, Inc. announced that it had received a Refuse to File (“RFT”) letter from the U.S. Food and Drug Administration (“FDA”) for its recently submitted New Drug Application for its lead candidate, Etripamil. In the RFT, the FDA noted that Milestone had not provided the agency with sufficient information to begin its review and sought additional information related to the timing of adverse events in the Milestone’s Phase 3 trial.
 
On this news, Milestone’s stock price fell $0.96 per share, or 33.33% in intraday trading.
 
If you purchased or otherwise acquired Milestone shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Milestone Pharmaceuticals Inc.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: